FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 170.77

Change

+2.94 (+1.75)%

Market Cap

N/A

Volume

9.50K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.51 (+0.33%)

USD 42.10B
FHLC Fidelity® MSCI Health Care In..

+0.25 (+0.35%)

USD 3.01B
FXH First Trust Health Care AlphaD..

+0.83 (+0.75%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.22 (+0.25%)

USD 0.23B
IDNA iShares Genomics Immunology an..

+0.24 (+0.98%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.12 (+0.31%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

+0.57 (+0.60%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.52 (+1.80%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.58 (+0.93%)

USD 0.02B
FTXH First Trust Nasdaq Pharmaceuti..

+0.04 (+0.13%)

USD 0.02B

ETFs Containing FBT

FBT:CA First Trust NYSE Arca Bio.. 99.96 % 0.00 %

N/A

CAD 1.83M
FHM:CA 0.00 % 0.78 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.04% 50% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.04% 36% F 40% F
Trailing 12 Months  
Capital Gain 16.56% 36% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.56% 36% F 42% F
Trailing 5 Years  
Capital Gain 38.34% 36% F 64% D
Dividend Return 1.79% 37% F 6% D-
Total Return 40.14% 36% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain 1.34% 24% F 43% F
Dividend Return 1.67% 24% F 34% F
Total Return 0.33% 42% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 12.27% 81% B- 72% C
Risk Adjusted Return 13.60% 33% F 34% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.